Key clinical point: Patients with neuromyelitis optica spectrum disorder experienced a reduction in attacks with inebilizumab, compared with those receiving placebo.

Major finding: Patients on inebilizumab experienced 31% fewer NMOSD attacks, compared with those receiving placebo, for a 77% relative reduction in risk of attacks.

Study details: Randomized, double-blind, phase 2/3 clinical trial with an open-label extension arm, enrolling 231 patients 3:1 to receive inebilizumab or placebo.

Disclosures: The study was funded by VielaBio and Medimmune, which are developing inebilizumab. Viela Bio also funded medical writing for the presentation. Dr. Cree reported receiving consulting fees from Abbvie, Akili, Alexion, Biogen, GeNeuro, Novartis, Sanofi Genzyme, and TG Therapeutics.